Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases

Neurodegenerative diseases such as Alzheimer’s disease have proven resistant to new treatments. The complexity of neurodegenerative disease mechanisms can be highlighted by accumulating evidence for a role for a growth factor, progranulin (PGRN). PGRN is a glycoprotein encoded by the GRN/G...

Full description

Bibliographic Details
Main Authors: Anarmaa Mendsaikhan, Ikuo Tooyama, Douglas G. Walker
Format: Article
Language:English
Published: MDPI AG 2019-03-01
Series:Cells
Subjects:
Online Access:http://www.mdpi.com/2073-4409/8/3/230
_version_ 1797701865227419648
author Anarmaa Mendsaikhan
Ikuo Tooyama
Douglas G. Walker
author_facet Anarmaa Mendsaikhan
Ikuo Tooyama
Douglas G. Walker
author_sort Anarmaa Mendsaikhan
collection DOAJ
description Neurodegenerative diseases such as Alzheimer’s disease have proven resistant to new treatments. The complexity of neurodegenerative disease mechanisms can be highlighted by accumulating evidence for a role for a growth factor, progranulin (PGRN). PGRN is a glycoprotein encoded by the GRN/Grn gene with multiple cellular functions, including neurotrophic, anti-inflammatory and lysosome regulatory properties. Mutations in the GRN gene can lead to frontotemporal lobar degeneration (FTLD), a cause of dementia, and neuronal ceroid lipofuscinosis (NCL), a lysosomal storage disease. Both diseases are associated with loss of PGRN function resulting, amongst other features, in enhanced microglial neuroinflammation and lysosomal dysfunction. PGRN has also been implicated in Alzheimer’s disease (AD). Unlike FTLD, increased expression of PGRN occurs in brains of human AD cases and AD model mice, particularly in activated microglia. How microglial PGRN might be involved in AD and other neurodegenerative diseases will be discussed. A unifying feature of PGRN in diseases might be its modulation of lysosomal function in neurons and microglia. Many experimental models have focused on consequences of PGRN gene deletion: however, possible outcomes of increasing PGRN on microglial inflammation and neurodegeneration will be discussed. We will also suggest directions for future studies on PGRN and microglia in relation to neurodegenerative diseases.
first_indexed 2024-03-12T04:41:50Z
format Article
id doaj.art-4e974167b5f0421fbcffb67fd53c9ad6
institution Directory Open Access Journal
issn 2073-4409
language English
last_indexed 2024-03-12T04:41:50Z
publishDate 2019-03-01
publisher MDPI AG
record_format Article
series Cells
spelling doaj.art-4e974167b5f0421fbcffb67fd53c9ad62023-09-03T09:35:24ZengMDPI AGCells2073-44092019-03-018323010.3390/cells8030230cells8030230Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative DiseasesAnarmaa Mendsaikhan0Ikuo Tooyama1Douglas G. Walker2Molecular Neuroscience Research Center, Shiga University of Medical Science, Otsu 520-2192, JapanMolecular Neuroscience Research Center, Shiga University of Medical Science, Otsu 520-2192, JapanMolecular Neuroscience Research Center, Shiga University of Medical Science, Otsu 520-2192, JapanNeurodegenerative diseases such as Alzheimer’s disease have proven resistant to new treatments. The complexity of neurodegenerative disease mechanisms can be highlighted by accumulating evidence for a role for a growth factor, progranulin (PGRN). PGRN is a glycoprotein encoded by the GRN/Grn gene with multiple cellular functions, including neurotrophic, anti-inflammatory and lysosome regulatory properties. Mutations in the GRN gene can lead to frontotemporal lobar degeneration (FTLD), a cause of dementia, and neuronal ceroid lipofuscinosis (NCL), a lysosomal storage disease. Both diseases are associated with loss of PGRN function resulting, amongst other features, in enhanced microglial neuroinflammation and lysosomal dysfunction. PGRN has also been implicated in Alzheimer’s disease (AD). Unlike FTLD, increased expression of PGRN occurs in brains of human AD cases and AD model mice, particularly in activated microglia. How microglial PGRN might be involved in AD and other neurodegenerative diseases will be discussed. A unifying feature of PGRN in diseases might be its modulation of lysosomal function in neurons and microglia. Many experimental models have focused on consequences of PGRN gene deletion: however, possible outcomes of increasing PGRN on microglial inflammation and neurodegeneration will be discussed. We will also suggest directions for future studies on PGRN and microglia in relation to neurodegenerative diseases.http://www.mdpi.com/2073-4409/8/3/230neuroinflammationgrowth factoranti-inflammatorymutationamyloidneurodegeneration
spellingShingle Anarmaa Mendsaikhan
Ikuo Tooyama
Douglas G. Walker
Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases
Cells
neuroinflammation
growth factor
anti-inflammatory
mutation
amyloid
neurodegeneration
title Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases
title_full Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases
title_fullStr Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases
title_full_unstemmed Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases
title_short Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases
title_sort microglial progranulin involvement in alzheimer s disease and neurodegenerative diseases
topic neuroinflammation
growth factor
anti-inflammatory
mutation
amyloid
neurodegeneration
url http://www.mdpi.com/2073-4409/8/3/230
work_keys_str_mv AT anarmaamendsaikhan microglialprogranulininvolvementinalzheimersdiseaseandneurodegenerativediseases
AT ikuotooyama microglialprogranulininvolvementinalzheimersdiseaseandneurodegenerativediseases
AT douglasgwalker microglialprogranulininvolvementinalzheimersdiseaseandneurodegenerativediseases